Blueshift Asset Management LLC Sells 14,079 Shares of Avantor, Inc. (NYSE:AVTR)

Blueshift Asset Management LLC reduced its stake in Avantor, Inc. (NYSE:AVTR) by 58.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 9,957 shares of the company’s stock after selling 14,079 shares during the quarter. Blueshift Asset Management LLC’s holdings in Avantor were worth $258,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AVTR. Versant Capital Management Inc lifted its holdings in shares of Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after purchasing an additional 1,102 shares in the last quarter. Blue Trust Inc. lifted its stake in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares in the last quarter. UMB Bank n.a. bought a new stake in Avantor in the 3rd quarter valued at approximately $49,000. Nisa Investment Advisors LLC boosted its position in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after acquiring an additional 1,285 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This trade represents a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AVTR. Wells Fargo & Company cut their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Barclays reduced their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird dropped their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. UBS Group reduced their price target on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, October 8th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Avantor has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Avantor Stock Up 0.1 %

Shares of AVTR opened at $21.04 on Friday. The firm has a market cap of $14.32 billion, a P/E ratio of 45.74, a price-to-earnings-growth ratio of 2.56 and a beta of 1.35. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor, Inc. has a 52 week low of $19.59 and a 52 week high of $28.00. The firm’s 50-day simple moving average is $23.40 and its 200 day simple moving average is $23.76.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.